Health Care & Life Sciences » Pharmaceuticals | IntelGenx Technologies Corp.

IntelGenx Technologies Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
948.00
1,659.00
5,095.00
5,220.00
5,195.00
1,824
Cost of Goods Sold (COGS) incl. D&A
72.00
-
604.00
830.00
1,108.00
719
Gross Income
876.00
-
4,491.00
4,390.00
4,087.00
1,105
SG&A Expense
2,681.00
3,599.00
3,210.00
5,519.00
6,883.00
10,392
EBIT
1,805.00
2,014.00
1,281.00
1,129.00
2,796.00
9,287
Non Operating Income/Expense
-
126.00
-
-
-
-
Interest Expense
-
-
123.00
203.00
569.00
1,121
Pretax Income
1,805.00
1,854.00
1,186.00
1,328.00
3,354.00
10,397
Income Tax
166.00
108.00
105.00
148.00
303.00
289
Consolidated Net Income
1,639.00
1,746.00
1,291.00
1,180.00
3,051.00
10,108
Net Income
1,639.00
1,746.00
1,291.00
1,180.00
3,051.00
10,108
Net Income After Extraordinaries
1,639.00
1,746.00
1,291.00
1,180.00
3,051.00
10,108
Net Income Available to Common
1,639.00
1,746.00
1,291.00
1,180.00
3,051.00
10,108
EPS (Basic)
0.03
0.03
0.02
0.02
0.05
0.14
Basic Shares Outstanding
54,023.70
63,182.20
63,524.00
63,956.50
66,152.80
74,121.90
EPS (Diluted)
0.03
0.03
0.02
0.02
0.05
0.14
Diluted Shares Outstanding
54,023.70
63,182.20
70,855.10
63,956.50
66,152.80
74,121.90
EBITDA
1,733.00
1,940.00
1,452.00
618.00
2,061.00
8,568
Non-Operating Interest Income
-
34.00
28.00
4.00
11.00
11

About IntelGenx Technologies

View Profile
Address
6420 Abrams
Ville Saint-Laurent Québec H4S 1X9
Canada
Employees -
Website http://www.intelgenx.com
Updated 07/08/2019
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast. It also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research and development, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.